Study of Options for Second-Line Effective Combination Therapy (SELECT)
Status:
Completed
Trial end date:
2014-10-29
Target enrollment:
Participant gender:
Summary
The study was conducted on people who were taking their first anti-HIV drug regimen
(including an Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), a type of anti-HIV
drug) but the drugs in this regimen were not doing a good job of fighting their HIV
infection.
The main purpose of this study was to compare two other anti-HIV drug regimens to see how
well they fight HIV. The study also looked at how well participants tolerate the drug
regimens and how safe they are.
The study was designed to determine whether taking the combination of lopinavir/ritonavir
(LPV/r) plus raltegravir (RAL) works as well as what is usually used for second-line therapy:
LPV/r plus the best-available nucleoside (nucleotide) reverse transcriptase inhibitor (NRTI)
combination. Testing a regimen that does not include any NRTIs was important because NRTIs
may no longer work for patients who received them as part of their first treatment regimen.
Phase:
Phase 3
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Abacavir Dideoxynucleosides Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lamivudine Lamivudine, zidovudine drug combination Lopinavir Raltegravir Potassium Ritonavir Tenofovir Zidovudine